- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024
- Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024
EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 “ 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 “ 11, 2024, in Baltimore, MD and virtually.
WFH 2024 World Congress
Madrid, Spain
April 21-24, 2024
Oral Presentation Metagenomi:
Potentially Curative Gene Editing Approach for Hemophilia A
Session: Late breaking session: New tech
Location: N103+N104
Date / time: Tuesday, April 23, 2024, 16:00 “ 17:00 CEST
ASGCT 2024 Annual Meeting
Baltimore, MD
May 7-9, 2024
Poster Novel CRISPR Effectors and Reverse Transcriptases Discovered from Metagenomics Enable Extensive Remodeling of the Human Genome
Abstract Number: 1209
Location: Exhibit Hall
Date / time: Thursday, May 9, 2024, 12:00 p.m. ET
Poster Novel and Efficient Base Editors Engineered to Comprehensively Target the Human Genome
Abstract Number: 684
Location: Exhibit Hall
Date / time: Wednesday, May 8, 2024, 12:00 p.m. ET
All presentations will be made available on the "News & Events," page in the Investors section of the Company's website at https://ir.metagenomi.co/news-events/events.
About Metageno mi
Metageno mi is a pre ci sion genet ic med i cines com pa ny com mit ted to devel op ing cura tive ther a peu tics for patients using its pro pri etary, com pre hen sive metage nomics-derived tool box. Metageno mi is har ness ing the pow er of metage nomics, the study of genet ic mate r i al recov ered from the nat ur al envi ron ment, to unlock four bil lion years of micro bial evo lu tion to dis cov er and devel op a suite of nov el edit ing tools capa ble of cor rect ing any type of genet ic muta tion found any where in the genome. Its com pre hen sive genome edit ing tool box includes pro gram ma ble nucle as es, base edi tors, and RNA and DNA-medi at ed inte gra tion sys tems (includ ing prime edit ing sys tems and clus tered reg u lar ly inter spaced short palin dromic repeat-asso ci at ed trans posas es). Metageno mi believes its diverse and mod u lar tool box posi tions the com pa ny to access the entire genome and select the opti mal tool to unlock the full poten tial of genome edit ing for patients. For more infor ma tion, please vis it https://‹metageno‹mi‹.co.
Cautionary Note Regarding Forward‹Looking Statements
This press release con tains ‹for ward-look ing state ments with in the mean ing of Sec tion 27A of the Secu ri ties Act of 1933 and Sec tion 21E of the Secu ri ties Exchange Act of 1934, each as amend ed. Such state ments, which are often indi cat ed by terms such as ‹antic i pate, ‹believe, ‹could, ‹esti mate, ‹expect, ‹goal, ‹intend, ‹look for ward to, ‹may, ‹plan, ‹poten tial, ‹pre dict, ‹project, ‹should, ‹will, ‹would and sim i lar expres sions, include, but are not lim it ed to, any state ments relat ing to our growth strat e gy and prod uct devel op ment pro grams, includ ing the tim ing of and our abil i ty to con duct IND-enabling stud ies, make reg u la to ry fil ings such as INDs and oth er appli ca tions and to obtain reg u la to ry approvals for our prod uct can di dates, state ments con cern ing the poten tial of ther a pies and prod uct can di dates, and any oth er state ments that are not his tor i cal facts. For ward-look ing state ments are based on management's cur rent expec ta tions and are sub ject to risks and uncer tain ties that could neg a tive ly affect our busi ness, oper at ing results, finan cial con di tion and stock val ue. Fac tors that could cause actu al results to dif fer mate ri al ly from those cur rent ly antic i pat ed include: risks relat ing to our growth strat e gy; our abil i ty to obtain, per form under, and main tain financ ing and strate gic agree ments and rela tion ships; risks relat ing to the results of research and devel op ment activ i ties; risks relat ing to the tim ing of start ing and com plet ing clin i cal tri als; uncer tain ties relat ing to pre clin i cal and clin i cal test ing; our depen dence on third-par ty sup pli ers; our abil i ty to attract, inte grate and retain key per son nel; the ear ly stage of prod ucts under devel op ment; our need for sub stan tial addi tion al funds; gov ern ment reg u la tion; patent and intel lec tu al prop er ty mat ters; com pe ti tion; as well as oth er risks described in ‹Risk Fac tors, in our most recent Form 10-K, on fil e with the SEC. We express ly dis claim any oblig a tion or under tak ing to release pub licly any updates or revi sions to any for ward-look ing state ments con tained here in to reflect any change in our expec ta tions or any changes in events, con di tions or cir cum stances on which any such state ment is based, except as required by law, and we claim the pro tec tion of the safe har bor for for ward-look ing state ments con tained in the Pri vate Secu ri ties Lit i ga tion Reform Act of 1995.
Investor Con tact:
Simon Harnest CIO, SVP Investor Relations
simon@‹metagenomi.‹co
Media Con tact:
Ash lye Hodge, Com mu ni ca tions Man ag er
ashlye@‹metagenomi.‹co